Canada Med Stop: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.canadamedstop.com in August 2025 and has observed that your website offers compounded semaglutide drug products. As described below, your claims concerning your compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

1. 1

   “The following claims concerning compounded semaglutide products appear on your website: • “The same active ingredient in branded weight loss medications.” • “FDA-Approved Medication” • “GENERIC””

2. 2

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

3. 3

   “If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

www.canadamedstop.com returned a live site on 2026-08-09 titled "Canadian Pharmacy - Canada Med Stop", with an ordering flow, account login and refill system, and "Ozempic (Semaglutide)" listed among its top medications — an operating storefront.

The word to stop on here is "GENERIC". A generic drug is a specific legal category: a copy approved by FDA after showing it performs the same as the original. A compounded drug is not that and cannot be, because no application was ever filed or approved for it. Putting the word on a compounded product borrows the one piece of reassurance that lets shoppers buy an unfamiliar cheaper version without a second thought, and "FDA-Approved Medication" beside it does the same job twice. The cross-border angle is the other half of what makes this letter practical. The closing paragraph about detention and refusal of admission is not decoration in a letter to a Canadian seller: a package that never clears the border is money spent for nothing, and that is a purchasing risk a domestic order does not carry. None of that makes the medication unsafe, and FDA does not say it is. It does mean two of the three phrases used to justify the price described a regulatory status the product never had.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Canada Med Stop failed to respond.